Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8569MR)

This product GTTS-WQ8569MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8569MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3856MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ7455MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ16000MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ3207MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ4848MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ931MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ2925MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ8955MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW